From isolation to exploration
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Search
Search results
Meira GTx announces positive data from phase clinical trial
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
Looking after your vision
It is important to avoid harming your vision, particularly if you have an inherited sight loss condition.
A new approach to treating inherited sight loss
A new approach to treating inherited sight loss
From isolation to exploration: what you can do to build your confidence when travelling
During Loneliness Awareness Week, we're hosting a special webinar to address the challenges faced by individuals with sight loss when it comes to travel and mobility.
Gene Therapy improves functional measures in XLRP
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Halloween Skydive 2023
This October, join Retina UK on Halloween weekend (28 and 29 October 2023) and face your fears by taking on a Halloween skydive at various airfields around the UK.
Bonfire Skydive 2023
This November, join Retina UK on Bonfire weekend (4 and 5 November 2023) and face your fears by taking on a Bonfire skydive at various airfields around the UK.
Skydiving
Various dates and locations available. Skydiving is an exhilarating experience, and you can do this while supporting our cause.
Look Forward – Winter 2023 – Issue 181
Inside this edition, register now for our AI webinar on 7 December with Dr Nikolas Pontikos.